SEC Form 4 · accession 0001562180-18-004454
G1 Therapeutics, Inc. · GTHX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Terry L Murdock
Officer — SVP of Development Operations
Period of report
Nov 5, 2018
Accepted (ET)
Nov 7, 2018 · 6:18 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001560241
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 5, 2018 | M | 3,519 | $13.51 | A | 3,519 | D | |
| Common StockF2 | Nov 5, 2018 | S | 3,519 | $41.5256 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to Buy)F3 | $13.51 | Nov 5, 2018 | M | 3,519 | D | — | Aug 1, 2027 | Common Stock | 3,519 | 85,924 | D |
Explanation of responses
- F1The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.
- F2The price represents the weighted average price with a low of $41.38 and a high of $41.99. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4.
- F3The shares underlying this option vested as to 25% of the shares on August 1, 2018, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.